Loring Wolcott & Coolidge Fiduciary Advisors LLP Amylyx Pharmaceuticals, Inc. Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $11.1 Billion
- Q3 2024
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 1,803 shares of AMLX stock, worth $6,977. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,803
Previous 1,803
-0.0%
Holding current value
$6,977
Previous $3,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AMLX
# of Institutions
127Shares Held
44.4MCall Options Held
235KPut Options Held
530K-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$18 Million1.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.09MShares$12 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$10.3 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY2.13MShares$8.23 Million0.18% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.02MShares$7.83 Million0.04% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $227M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...